Here we go again...

"Getting insulin in pill form past the stomach will be a game changer in the treatment of diabetes. Failed attempts by Pfizer (PFE) at inhalable insulin Exubera, which promised to bring in $2 billion, caused the company to roll back a clumsy device off the market with a $2.8 billion write-off. The future of Mannkind's (MNKD) inhalable Afrezza has also remained uncertain after clinical trials stalled at the FDA."

http://seekingalpha.com/article/1553202-oramed-an-early-stage-biotech-company-with-huge-potential?source=feed